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C ONTRI BUTIO N S

Psychotropics and Sudden Cardiac Death
TUAN ANH DINH; JESSICA L. GÖREN, PHARMD, BCPP

A BST RA C T

Over the past two decades there has been a large increase
in the number of patients prescribed psychotropic medications. Many of these agents are associated with QTc
prolongation which is considered a marker for increased
risk of sudden cardiac death due to malignant arrhythmias such as Torsades de pointes (TdP). Psychotropics
rarely lead to sudden death in healthy individuals on a
single QTc prolonging medication. However, factors such
polypharmacy, recent initiation of a QTc prolonging medication, bradycardia, electrolyte abnormalities and preexisting arrhythmias increase the likelihood of psychotropic-induced sudden cardiac death. Therefore, clinicians
must recognize which psychotropics and risk factors are
associated with increased risk in order to minimize the
risks of psychotropic QTc prolongation.
psychotropic, side effect, cardiac, QTc,
Torsades, arrhythmia
K E YWORD S:

INTRO D U C T I O N
There has been increasing concern regarding the cardiac side
effects of psychotropics. Some psychotropic medications increase the risk of sudden cardiac death. However, these drugs
are important for many patients. Therefore, it is important
to assess cardiac risks associated with psychotropics. This
article will summarize these effects and provide recommendations on cardiac risk assessment for patients treated with
psychotropic medications.

The QT interval and Torsades de pointes
The QT interval is the measure of cardiac conduction speed
that starts from the beginning of a QRS wave and ends with
the T wave on an electrocardiogram (ECG). Usually the
length of the QT wave decreases as heart rate increases, so
a corrected value (QTc) is used to assess cardiac conduction.
QTc is measured in milliseconds and the average QTc is between 430 and 450 milliseconds. (Table 1) Females usually
have a slower cardiac conduction rhythm than males and
thus a longer QTc.1-3 The QTc varies by up to 10 milliseconds
during the course of a day with maximal intervals during the
first few hours of awakening.4
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Prolonged QTc intervals can lead to ventricular tachyarrhythmia and TdP. While the true incidence of TdP is unknown, the number of reported cases is low. Over a period
of 15 years only 761 cases were reported to the World Health
Organization.5 Therefore, prolonged QTc has become a
surrogate marker for TdP.1,5
It is important to note that drug induced QTc prolongation alone rarely leads to TdP. A review of population studies
reported prolonged QTc was associated with TdP in patients with preexisting cardiovascular disease, but not with
healthy patients.6 Rather TdP is most likely to occur when
prolonged QTc is combined with at least two risk factors
such as electrolyte abnormalities, bradycardia or congenital cardiac abnormalities. The most important risk factors
appear to be preexisting heart disease, age >65 years, and
female sex. 6,7 Torsades de pointes may be increased in hospitalized patients because hospitalized patients are more
likely to have risk factors such as heart disease, advanced age,
bradycardia or electrolyte disturbances than outpatients.8
QTc prolongation is often dose dependent but the maximal effect of many drugs is limited.6 Therefore, massive
drug overdoses of QTc prolonging medications do not
necessarily result in severe QTc prolongation or TdP.

Psychotropics and QTc
Psychotropics, such as antidepressants and antipsychotics,
affect the heart by blocking certain potassium channels.
This leads to a blockade of type IKr (a fast potassium channel in the heart), causing a delay in repolarization and thus
QTc prolongation.1,2 This is accomplished via either HERG
(Human ether-a-go-go Related Gene) blockade or abnormal
protein trafficking for HERG. Almost all drugs which can
induce TdP block HERG, while a few indirectly affect HERG
function.1,2 Drugs which prolong the QTc by alternate means
are less likely to result in TdP.
Table 1. Average QTc1-3

MEN

WOMEN

<430

<450

BORDERLINE

431-450

451-470

PROLONGED

>450

>470

NORMAL
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Population-based studies indicate there is a two- to threefold increased risk of sudden cardiac death in patients taking
non-cardiac QTc prolonging medications.6,7 Antidepressants
are the psychotropic class most commonly associated with
TdP (9%).7,9,10 For antipsychotics, it is estimated there are
10-15 sudden cardiac deaths/10,000 years of observation,
and only a small proportion of these deaths are likely attributable to TdP.11 Risk of QTc prolongation with other psychotropics such as benzodiazepines and anticonvulsants is low.
Risk is of sudden cardiac death is highest in the first 90
days of initiating, increasing the dose or adding an interacting medication. Female sex, polypharmacy, congenital long
QT syndrome, electrolyte abnormalities, increasing age and
higher doses of QTc prolonging medication all increase the
likelihood of experiencing drug induced QTc prolongation.10,11
While studies have reported psychotropics increase patients’ average QTc, the QTc interval typically remains less
than 500 milliseconds, considered a clinically relevant indicator of TdP risk.4,10,11 In patients with schizophrenia a
reported history of arrhythmia and other metabolic factors
had greater influence on the prolongation of QTc interval
than use of psychotropics alone.9 Therefore, it seems likely
psychotropic induced QTc prolongation is unlikely to lead
to TdP in the absence of other risk factors.

Antipsychotics and QTc
Although large epidemiologic studies have reported firstand second-generation antipsychotics are associated with
increased risk of sudden cardiac death, the absolute risk of
death remains quite low.1,3,6,7,9-14 In addition, while numerous antipsychotics have been shown to prolong the QTc
(Table 2), relatively few antipsychotics have been associated
with TdP.1,3,13,14 Thioridazine, pimozide and ziprasidone are
known to cause the greatest QTc prolongation while quetiapine, risperidone and clozapine are associated with lower
risk.1,12-14 Significant evidence of antipsychotic induced TdP
is only associated with mesoridazine, thioridazine and haloperidol.1,15 While haloperidol has been linked to TdP, risk
is much lower than with thioridazine.1,13,14 Aripiprazole
appears to have a lower risk of QTc prolongation, although
there is one well documented case report of QTc prolongation with low dose monotherapy aripiprazole.13-16

Antidepressants and QTc
Large epidemiologic trials have demonstrated an elevated
risk of sudden cardiac death with tricyclic antidepressants
(TCAs). TCAs have been shown to prolong the QTc 10-25 ms
and cases of TdP have been reported with most, although not
all, TCAs.13-15 Newer antidepressants have less risk of QTc
prolongation and sudden cardiac death compared with TCAs
although QTc prolongation of 5-12 ms and cases of TdP have
been reported for citalopram, fluoxetine and paroxetine.13-15
Reports of QTc prolongation are mixed with the serotonin
norepinepherine reuptake inhibitors (SNRIs). However, for
both SSRIs and SNRIs, risk appears to be greatest in patients
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with preexisting risk factors or those with elevated blood
concentrations due to over dose, high doses or drug interactions. Bupropion, mirtazapine and trazodone all appear to
have minimal risk of QTc prolongation at typical doses.15

Table 2. Mean QTc prolongation and psychotropics12-15

DRUG

MEAN QTc (msec)

ANTIDEPRESSANTS

TCAs

>16

Mirtazapine

5-8

Trazodone

5-8

Venlafaxine

4.7

Duloxetine

0

Fluoxetine

9-16

Citalopram

8-10

Escitalopram
Paroxetine
Fluvoxamine

4.5
1–4
0-2

Sertraline

0

Bupropion

0

ANTIPSYCHOTICS

Thioridazine

25-30

Ziprasidone

5-22

Pimozide

13

Clozapine

8-10

Iloperidone

9

Haloperidol

7

Quetiapine

6

Risperidone

0-5

Olanzapine

2

Asenapine

2-5

Aripiprazole

0
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Psychotropic Polypharmacy and QTc
The risk of QTc prolongation with antipsychotics and
antidepressants is typically dose related.1,4,5,10 Therefore any
combination of medications which results in elevated concentrations of antidepressants or antipsychotics increases
the likelihood of QTc prolongation. Conversely, any psychotropic that increases the concentration of non-psychotropic
QTc prolonging medications increases the risk of drug induce arrhythmia. Additionally, the risk of sudden cardiac
death is increased in patients on multiple QTc prolonging
medications, whether the psychotropics are combined with
other QTc prolonging psychotropic or non-psychotropic
medications. Thus careful consideration should be given to
utilization of psychotropic polypharmacy and combinations
of psychotropics and non-psychotropic medications.

Monitoring
Psychotropic drugs are known to affect the QTc interval
and should be utilized with caution in patients with risk
factors such as age >65, female gender, congenital long QTc
syndrome, electrolyte abnormalities, polypharmacy and preexisting cardiac disease.1,13-15 For relatively healthy patients
without preexisting risk factors, routine ECG monitoring
should be considered for those with episodes of blackouts,
fainting, seizures, or with unexplained lightheadedness,
palpitations or dizziness.15 A baseline ECG should be considered in patients who are on multiple QTc prolonging medications or on high risk medications such as thioridazine. An
ECG recording should be obtained for patients with any risk
factors before treatment with a QTc prolonging psychotropic is started and once the medications are at steady state.
If the QTc is mildly elevated consider lowering the dose or
utilizing another agent with less potential for QTc prolongation. In patient whose QTc exceeds 500 milliseconds or
whose QTc increases >60 milliseconds when starting a new
psychotropic consider discontinuation of QTc prolonging
psychotropics or switching to agents with a lower propensity for QTc prolongation. Electrolytes should be monitored
in patients taking diuretics or those with severe diarrhea,
vomiting or other risk factors for electrolyte imbalances. 1,13-14

T REAT M E N T RE C O M M E NDAT I ONS
The risk of TdP is low in patients who are relatively healthy
without cardiac disease. Therefore, for patients who do not
have other risk factors, it is reasonable to use psychotropic
medications that may prolong the QTc. For patients with prolonged QTc of <500 milliseconds at baseline, psychotropic
medications are a reasonable treatment with ECG monitoring.
Since the risk is highest during the first 90 days after starting a medication, healthy patients on a stable regimen with
a prolonged QTc of < 500 milliseconds can be continued
on their current medication regimen. If the patient develops other risk factors, ECG is a useful tool for reevaluating the medication regimen. If the dose of a QTc prolonging
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medication is increased, a pre- and post-baseline ECG will
be useful in determining risk of the dose increase.
For patients with a prolonged QTc of ≥ 500 milliseconds,
consider discontinuing any QTc prolonging medications
and/or substituting with medications less likely to prolong
the QTc. Also, consider consulting a cardiologist.

SU M M A RY
Since psychotropic-induced QTc prolongation is typically
dose related, patients should be maintained on the lowest
effective doses of psychotropics. Additionally, careful review
for drug interactions should be conducted prior to adding any
medications to ongoing psychotropic treatment. The risk of
psychotropic-induced QTc prolongation is highest when a
medication is started, reaches steady state or after dose increases. Therefore, patients successfully treated for >90 days
are less likely to experience psychotropic induced arrhythmias unless there are changes in medication treatment or
new risk factors. Sudden cardiac death is unlikely in patients
without preexisting risk factors and is a rare outcome for those
with risk factors. Even for patients with risk factors who may
have a prolonged QTc that is < 500 milliseconds, treatment
with a psychotropic may be reasonable with appropriate
monitoring. Physicians should not be discouraged from psychotropic use unless patients have a contraindication, such
as a cardiac arrhythmia or congenital long QT syndrome.
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